TSX-049 SUCCESSFULLY COMPLETED CONFIRMATIVE STUDY

TesoRx has successfully demonstrated in clinical studies that the oral delivery platform with testosterone was safe and efficacious in over 150 patients. TesoRx successfully completed a confirmative study in canines that was designed to predict the pharmacokinetic profile of the optimized TSX-049 formulation for the oral treatment of hypogonadism. The results of the study confirmed that the optimized TSX-049 formulation has enhanced bioavailability and a dose response sufficient to overcome negative feedback of gonadal testosterone production. TesoRx will be advancing TSX-049 into Phase 1/2a human clinical trial and anticipates a potential U.S. Food and Drug Administration approval as soon as 2025.